mRNA vaccine factory project in Rwanda (design, build, finance, operate, maintain and transfer)
- Value
- Undisclosed
- Date
- 10 October 2026
- Transaction type
- Other
- Practice area
- Project Finance and Infrastructure
- Sector
- Healthcare and Pharmaceuticals
- Jurisdiction
- Rwanda
- Client
- Government of Rwanda / public institution
Summary
mRNA vaccine factory project in Rwanda (design, build, finance, operate, maintain and transfer).
Bulk drug substance and drug product manufacturing facility; value not disclosed.
Why it matters
Significant / value undisclosed
Scope of legal work
ENSafrica (ENSafrica Rwanda)
Advisers
Other parties
Government of Rwanda / public institution (acquirer or client); Major global pharmaceutical company (counterparty or seller)
Other advisers
ENS Rwanda firm brochure
Sources
Compiled by Meridian from the public announcements and filings listed under Sources.
Spotted an error? Suggest a correction.
Related
Related reporting
Intelligence
Kenya’s Trust Administration Act 2026 takes effect with new trust registry
Kenya's Trust Administration Act, 2026, signed on 8 September, took effect on 25 September.
Intelligence
Ghana: deep talent, thin flow, and a US$19.9bn transaction nobody outside Accra has heard of
Project Wembley is reported by counsel as the largest M&A transaction in Ghana's beverages manufacturing sector in recent history. Four firms on a single mid-market fintech…
Intelligence
Brands, broadcast rights and code: what 99 IP-linked deals reveal about Africa’s IP market
Meridian tracked 99 IP-linked transactions across Africa from October 2024 to October 2026. Brand licences, content rights and software now set prices in African M&A.